Fourth SARS-CoV-2 vaccination also protects cancer patients JAMAOnc
Supervision:Dr Mair reported receiving nonfinancial support from Pierre Fabre outside the submitted work. Dr Valenta reported receiving personal fees from Viravaxx AG and Worg Pharmaceuticals; receiving grants from HVD Biotech, Viravaxx AG, and Worg Pharmaceuticals outside the submitted work; and holding a patent for Molecular Interaction Assay and a patent for SARS-CoV-2 vaccine .
This study was also funded from the research budget of the Medical University of Vienna and the budget of the Südtiroler Sanitätsbetrieb.The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Barbara Ziegler provided excellent technical assistance. Rainer Puhr, PhD ; Anna S.